Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-01
2011-03-01
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S613000, C536S018700, C554S035000
Reexamination Certificate
active
07897580
ABSTRACT:
The invention relates to the use of β-glycolipids as immunomodulators. More particularly, the invention relates to the use of β-glycolipids, preferably, β-lactosyl-ceramide, β-glucosylceramide, β-galactosyl-ceramide, ceramid and β-lactosyl-ceramide, as well as any mixture or combination thereof for the treatment of immune related disorders. The present invention further relates to a process for the modulation of the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells, in a subject suffering from an immune related disorder. Therapeutic compositions and method for the preparation of these compositions are also provided.
REFERENCES:
patent: 5686426 (1997-11-01), Martel et al.
patent: 7488491 (2009-02-01), Tsuji et al.
patent: 0 718 787 (1996-07-01), None
patent: 1452181 (2004-09-01), None
patent: WO 00/24406 (2000-05-01), None
patent: WO 02/051986 (2002-07-01), None
patent: WO 2005/014008 (2005-02-01), None
patent: WO 2005/032462 (2005-04-01), None
Sigma Biochemicals and Reagents for Life Science Research Catalog, St. Louis, MO, 2000-2001, only pp. 226-227 supplied.
Nelson & Cox, “Lehninger—Principles of Biochemistry, 4th Edition,” W. H. Freeman and Co., New York, NY, 2005, only pp. 352-353 supplied.
Lehninger, A. L., “Biochemistry—The Molecular Basis of Cell Structure and Function, 2nd Edition,” Worth Publishers, Inc., New York, NY, Jul. 1978, only pp. 676-677 supplied.
Hara et al., “Occurrence of Sulfatide as a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins,” The Journal of Biochemistry (Japan), 102(1), 83-92 (Jul. 1987).
International Search Report for PCT/IL2006/001217 (claiming priority to same Israeli case), Mar. 21, 2007.
International Preliminary Report on Patentability for PCT/IL2006/001217, Mar. 21, 2007.
Adorini, L. et al. Immunol. Today, Pathogenesis and Immunotherapy of autoimmune diseases, vol. 18:209-211 (1997).
Angulo, P. N. Eng. J. Med., Nonalcoholic Fatty Liver, vol. 346, No. 16:1221-1231 (2002).
Bleicher, P.A. et al., Science, Expression of Murine CD1 on Gastrointestinal Epithelium, vol. 250:679-682 (1990).
Caldwell, S.H. et al., Hepatology, Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease, vol. 29:664-669 (1999).
Chandra, R.K. et al., Acta. Paediatr. Scand, Immunocompetence in Obesity, vol. 69:25-30 (1980).
Chiba, M. et al. Gut, Human colonic intraepithelial and lamina proprial lymphocytes:cytotoxicity in vitro and the potential effects . . . vol. 22:177-186 (1981).
Cohen, B. et al., Science, Modulation of Insulin Activities by Leptin, vol. 274:1185-1188 (1996).
Collins, C. et al., Eur. J. Immunol., RAGI, RAG2 and pre-T cell receptor α chain expression by adult human hepatic T cells: evidence for extrathymic T cell maturation, vol. 26:3114-3118 (1996).
Cortez-Pinto, H. et al., JAMA, Alterations in Liver ATP Homeostasis in Human Nonalcoholic Steatohepatitis, vol. 282, No. 17:1659-1664 (1999).
Das, K.M., et al. Gastroenterology, A Shared and Unique Epitope(s) on Human Colon, Skin, and Biliary Epithelium Detected by a Monoclonal Antibody, vol. 98:464-469 (1990).
Dasgupta, A. et al. Gut, Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody, vol. 35:1712-1717 (1994).
Diehl, A.M. Am. J. Physiol. Gastrointest. liver Physiol.,Nonalcoholic Steatosis and Steatohepatitis: IV. Nonalcoholic fatty liver disease abnormalities . . . vol. 282:G1-G5 (2002).
Faggioni, R. et al., Proc. Natl. Acad. Sci. USA, Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity . . . vol. 97:2367-2372 (2000).
Feingold, K.R. et al., Diabetes, Role of Cytokines in Inducing Hyperlipidemia, vol. 41:97-101 (1992).
Field, C.J. et al., Am. J. Clin. Nutr., Changes in circulating leukocytes adn mitogen responses during very-low-energy all-protein reducing diets, vol. 54:123-129 (1991).
George, D.K. et al., Gastroenterology, Increased Hepatic Iron Concentration in Nonalcoholic Steatohepatitis . . . vol. 114:311-318 (1998).
Hibi, T. et al., Clin. Exp. Immunol.,Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis, vol. 54:163-168 (1983).
Hotamisligil, G.S. et al., Journal of Internal Medicine, The role of TNF α and TNF receptors in obsesity and insulin resistance, vol. 245:621-625 (1999).
Hotamisligil, G.S. et al., Science, Adipose Expression of Tumor Necrosis Factor- α : Direct Role in Obsesity-Linked Insulin Resistance, vol. 259:87-91 (1993).
Howard, J.K. et al, J. Clin. Invest., Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice, vol. 104:1051-1059 (1999).
Hruszkewycz, A.M. Biochem. Biophys. Res. Commun., Evidence for Mitochondrial DNA Damage by Lipids Peroxidation, vol. 153:191-197(1988).
Koffler, M. et al., Diabetes, Immunobiological Consequence of Regulation of Insulin Receptor on Alloactivated Lymphocytes in Normal and Obese Subjects, vol. 40:364-370 (1991).
Krishnan, E.C. et al., J. Surg. Res., Study of Function and Maturation of Monocytes in Morbidly Obese Individuals vol. 33:89-97 (1982).
Loffreda, S. et al., FASEB J.,, Leptin regulates prooinflammatory immune responses, vol. 12:57-65 (1998).
Lord, G.M. et al., Nature, Leptin modulates the T-cell immune response and reverses starvation-induced immunosupression, vol. 394:897-901 (1998).
Mabuchi, A. et al., J. Leukocyte Biology, Role of the liver in T cell differentiation—generation of CD3-CD4+/CD8+TCR β -cells and CD3-4-8-TCRβ +cells from CD4-8-TCRB -athymic nude bone marrow cells by culture with parenchymal liver cells vol. 63:575-583 (1998).
Madsen, K.L. et al., Gastroenterology, Interleukin 10 Prevents Cytokine-Induced Disruption of T84 Monolayer Barrier Integrity and Limits Chloride Secretion, vol. 113:151-159 (1997).
Mattacks, C.A. et al., Cytokine, Interactions of Noradrenalin and Tumour Necrosis Factor α, Interleukin 4 and Interleukin 6 in the Control of Lipolysis from adipocytes around lymph nodes, vol. 11, No. 5:334-346 (1999).
Matteoni, C.A. et al., Gastroenterology, Nonalcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological Severity, vol. 116:1413-1419 (1999).
Mitchell, D.G. et al., Invest. Radiol., Chemical Shift Phase-Difference and Suppression Magnetic Resonance Imaging Techniques in Animals, Phantoms, and Humans, vol. 26:1041-1052 (1991).
Mizoguchi, A., et al., J. Exp. Med., Cytokine Imbalance and Autoantibody Production in T Cell Receptor- α Mutant Mice with Inflammatory Bowel Disease vol. 183:847-856, (1996).
Montague, C.T. et al., Diabetes, Depot-Related Gene Expression in Human Subcutaneous and Omental Adipocytes, vol. 47:1384-1391 (1998).
Neurath, M. et al., J. Exp. Med., Experimental Granulomatous Colitis in Mice Is Abrogated by Induction of TGF- α -mediated Oral Tolerance, vol. 183:2605-2616 (1996).
Hiroko Ogawa et al, Biochimica et Biophysica Acta, Cachectin/tumor necrosis factor and interleukin-1 show different . . . , vol. 1003 (1989) 131-135.
Pelleymounter, M.A. et al., Science, Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice, vol. 269:540-543 (1995).
Podolsky, D.K. et al., New Engl. J. Med., Inflammatory Bowel Disease, vol. 325:928-937(1991).
Pond, C.M. et al., Proceedings of the nutrition society, Long-term changes in adipose tissue in human disease, vol. 60:365-374 (2001).
Powrie, F. et al., Immunity, Inhibition of Th1 Responses Prevents Inflammatory Bowels Disease in scid Mice Reconstituted with CD45RBhi CD4+ T Cells vol. 1:553-562 (1994).
Purohit, A. et al., Journal of Clinical Endocrinology and Metabolism, Aromatase Activity and Interleukin-6 Production by Normal and Malignant Breast Tissues, vol. 80:3052-58 (1995).
Raedler, A. et al., Clin. Exp. Immunol., Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc α receptors, vol. 60:518-524 (1985).
Rosen, B.S. et al., Science, Adipsin and
Bogdanos Natalie
Crane Lawrence E
LandOfFree
β glycolipids as immuno-modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β glycolipids as immuno-modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β glycolipids as immuno-modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688690